Spots Global Cancer Trial Database for cytosine arabinoside
Every month we try and update this database with for cytosine arabinoside cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) | NCT02101983 | Acute Myeloid L... | Cytosine Arabin... | 55 Years - 65 Years | University of Rochester | |
| PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | NCT01358201 | Acute Lymphobla... | vINCRISTINE Dexamethasone Methotrexate Cytosine arabin... | 55 Years - | PETHEMA Foundation | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML | NCT02891278 | Acute Myeloid L... | Sertraline Cytosine arabin... allogeneic stem... | 18 Years - 70 Years | Columbia University | |
| LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | NCT00526305 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone L-Asparaginase Mitoxantrone Cytosine Arabin... Hydrocortisone Mercaptopurine Cyclophosphamid... Dexamethasone | - 65 Years | PETHEMA Foundation | |
| LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia | NCT00526409 | Acute Lymphobla... | Prednisolone Daunorubicin Vincristine L-Asparaginase Cyclophosphamid... Methotrexate Cytosine Arabin... | - 16 Years | PETHEMA Foundation | |
| Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | NCT00199186 | Philadelphia Po... Lymphoid Blasti... | imatinib vincristine cyclophosphamid... cytosine arabin... dexamethasone idarubicin methotrexate (i... AraC (intrathec... dexamethasone (... | 56 Years - | Johann Wolfgang Goethe University Hospital | |
| Treatment of High Risk Adult Acute Lymphoblastic Leukemia | NCT00853008 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone Mitoxantrone Cytosine Arabin... Dexamethasone Methotrexate (M... Cytarabine ASP Mercaptopurine Teniposide Hydrocortisone | 16 Years - | PETHEMA Foundation | |
| S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML | NCT00085709 | Leukemia | gemtuzumab ozog... observation Cytosine arabin... Daunomycin | 18 Years - 60 Years | SWOG Cancer Research Network | |
| Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia | NCT00081822 | Acute Myeloid L... | clofarabine Ara-C | 60 Years - | University of Alabama at Birmingham | |
| PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | NCT01358201 | Acute Lymphobla... | vINCRISTINE Dexamethasone Methotrexate Cytosine arabin... | 55 Years - | PETHEMA Foundation | |
| Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) | NCT02101983 | Acute Myeloid L... | Cytosine Arabin... | 55 Years - 65 Years | University of Rochester | |
| Treatment of High Risk Adult Acute Lymphoblastic Leukemia | NCT00853008 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone Mitoxantrone Cytosine Arabin... Dexamethasone Methotrexate (M... Cytarabine ASP Mercaptopurine Teniposide Hydrocortisone | 16 Years - | PETHEMA Foundation | |
| A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) | NCT00495287 | Acute Myelogeno... | cytosine arabin... | 16 Years - 65 Years | Northern Italy Leukemia Group | |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | NCT02722733 | Hodgkin's Lymph... Non-Hodgkin's L... | G-CSF (filgrast... Cytosine arabin... | 18 Years - 65 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | NCT02722733 | Hodgkin's Lymph... Non-Hodgkin's L... | G-CSF (filgrast... Cytosine arabin... | 18 Years - 65 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy | NCT03054883 | Mantle Cell Lym... | 18 Years - | Czech Lymphoma Study Group | ||
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | NCT01358201 | Acute Lymphobla... | vINCRISTINE Dexamethasone Methotrexate Cytosine arabin... | 55 Years - | PETHEMA Foundation | |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. | NCT01908621 | Multiple Myelom... | G-CSF (filgrast... Cytosine arabin... | 18 Years - 65 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia | NCT00081822 | Acute Myeloid L... | clofarabine Ara-C | 60 Years - | University of Alabama at Birmingham | |
| LAL-BR/2001: Study Treatment to Low Risk ALL | NCT00526175 | Acute Lymphobla... | Prednisone Vincristine Daunorubicin L-Asparaginase Cyclophosphamid... Methotrexate Cytosine Arabin... Mercaptopurine VP-16 | - 15 Years | PETHEMA Foundation | |
| PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML | NCT00303290 | Chronic Myeloid... | Peg Interferon ... Ara-C (cytosine... | 12 Years - | M.D. Anderson Cancer Center | |
| Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | NCT00199186 | Philadelphia Po... Lymphoid Blasti... | imatinib vincristine cyclophosphamid... cytosine arabin... dexamethasone idarubicin methotrexate (i... AraC (intrathec... dexamethasone (... | 56 Years - | Johann Wolfgang Goethe University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
